It's called triple-negative breast cancer and it manifests itself in the lack of expression of two cell surface proteins -- estrogen and progesterone receptors -- and also the protein HER2.

It's a disease that does not typically respond to treatment with standard chemotherapy drugs and therefore, diagnosis can come with a poor prognosis. But a new study out of Massachusetts General Hospital Cancer Center in Boston indicates this type of disease is sensitive to the drug cisplatin.

The study, appearing online in the April 19 Journal of Clinical Investigation and in the journal's May print issue, shows that triple-negative breast cancer expresses larger amounts of two proteins, delta-Np63 and TAp73. Delta-Np63 binds to TAp73 and prevents it from killing cancerous cells. Cisplatin does the trick, though, and releases TAp73 from delta-Np63. This causes the cells to die and offers hope for a sometimes hopeless disease.

Photographer Sharon Seligman's images are inspired by her personal journeys. She photographs people and birds and residential communities. She also captures the journeys of women enduring breast cancer. Her work speaks of the human experience. It speaks of her own experience. It speaks volumes.

Bearing Witness: Beyond the Surface of Breast Cancer is one of Seligman's portfolios. It's a photographic trip down memory lane, depicting self-portraits of courageous breast cancer survivors. Seligman tells her own story in words that border the left side of each portrait. Captions to the right of each black and white photograph offer a glimpse into the life of each woman whose being is displayed in raw form, for all to see, for all to contemplate, for all to appreciate.

And then in another portfolio, Seligman offers more photographs, more visions of the breast cancer experience.

Seligman aims to share the physical changes that come from breast cancer, to project the inner truths. Clearly, she is right on target.

The breast cancer drug Tykerb may be one of the future wonder drugs available for women left with limited options for treating advanced-stage disease.

Tykerb, manufactured by British-based GlaxoSmithKline PLC, is currently an experimental drug that delays growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin -- a targeted drug that significantly decreases chances of recurrence for women with HER2 positive breast cancer. Herceptin blocks the swift growth of an aggressive protein on the cell's surface while Tykerb does its work on the inside of the cell. Herceptin is given intravenously. Tykerb is given in pill form.

Two previous posts -- one in April and one in June -- relfect the progress of Tykerb as reported in the media. With each new report, Tykerb seems to gain momentum and promise. And this past week, new reports revealed new promise as Glaxo began seeking regulatory approval of the Tykerb pill in Europe.

Glaxo has filed an application with the Food and Drug Administration for approval of this drug and is preparing to market the drug for the treatment of advanced breast cancer in women. Glaxo hopes to launch Tykerb -- also known as lapatinib ditosylate -- next year.

It's day 15 in this Breast Cancer Awareness Month and the survivors spotlighted on this site are stacking up. Yet we've only just scratched the surface of breast cancer survivor stories. And by the end of October, we will have only featured a very small sample of survivors everywhere. There are countless others with their own powerful stories. It's sad there are so many stories shaped by breast cancer. It's empowering too -- because breast cancer survivors are a passionate bunch. They are passionate in their fights, passionate in their beliefs, passionate in their willingness to help others.

A passionate bunch of survivors can be found here on The Cancer Blog. They are all women, of various ages, with various backgrounds, defined by different experiences. They are also quite the same -- for they have all been touched by breast cancer. And their words of wisdom are strikingly similar, despite the contrast in characteristics that define these women and their very individual battles with breast cancer.

Here are seven survivor similarities worth spotlighting.

Can a spoonful of sugar treat cancer? No. Actually, the lack therof, might prove a valuable tool in halting the spread of cancer. Leading scientist Dr Robert Falconer is trying to develop new drugs based on the knowledge that there exists on the surface of cancer cells 200 identical simple sugars that make up a long molecule called polysialic acid -- and the more polysialic acid on cancer cells the easier the spread of cancer cells.

And if you are thinking -- well -- that sounds like a rather simplistic explanation of the science behind the research Dr Falconer is involved in regarding the study of sugars on the surface of cancer cells -- you might be right. Then again, according to Dr Falconer, it might be rather simple and yet largely ignored as it has been in preference of research that has focused more on the proteins found on the surface of cancer cells.

The surface of cells carries a complex mixture of proteins and sugars.

The Association for International Cancer Research (AICR) thinks Dr Falconer might be on to something, as they are providing funding for three years of additional research into finding new molecules to stop the increased polysialic acid production cancer cells seem to count on before their move beyond the original tumor location.

My mammogram and ultrasound today revealed nothing but normal, healthy tissue. The doctor said my pictures looked beautiful -- and she could find not one thing to worry about. She really looked for something -- because I was convinced there was something wrong when I found a lump-like bump in my left breast two weeks ago. So convinced that I was riddled with anxiety and panic and fear. But now I am happy and content once again -- and relieved that my fears were unfounded.

The explanation my doctor offered for the lumpiness I detected goes like this: my breast has been swollen and plump ever since my lumpectomy and radiation over the course of almost two years. Slowly, the swelling is disappearing and so all the tissue hidden under the plumpness is coming to the surface. It's always been there -- she could see it when she looked at my previous mammograms -- but I haven't noticed. Now, it's become more apparent as my breast returns to its normal size and shape. And so it seemed new to me. And suspicious. And wrong. But it's okay. It's normal. It's nothing to worry about.

And so I am not worried. I am settled and calm and thrilled to be surviving breast cancer, without fear that the disease is coming back. At least for today.

A reader left a comment the other day on the Cancer Blog post death by cancer dims outlook of promise, hope, survival. It was positive and supportive and inspiring -- and sad too. The reader shared that her mother passed away in February after a year-long battle with gallbladder cancer. She wrote that her mother handled her diagnosis, chemotherapy, transfusions, medications -- and her final days -- with true grace. And this is a big deal. Because there is not much information floating around on the topic of this cancer. So this woman didn't have much to cling to. Like I do. As a breast cancer survivor, I have mounds of resources at my disposal. I have books and magazines and websites and blogs that devote generous coverage to breast cancer. There are walks and runs and yard sales and fashion shows and other fundraisers that make breast cancer survivors the lucky recipients of extensive research and study. I see pink ribbons all over town and license plates on the roads and clothing and hats and even tennis shoes that promote breast cancer awareness. I could go on -- and on and on.

Gallbladder cancer is rare. So perhaps that's why there is not an abundance of information on the disease that has no known cause or test to detect its presence in the body. The American Cancer Society estimates that about 8,750 new cases of gallbladder cancer and bile duct cancer (excluding bile ducts within the liver) will be diagnosed in 2006 in the United States. And about 3,260 people will die of these cancers in 2006. Of these new cases and deaths, about half are due to gallbladder cancer, which affects predominantly women and those who are older than 65. Diagnosis of this cancer is difficult because symptoms do not often surface until the late stages when aggressive treatment becomes necessary. Surgery, chemotherapy, and radiation therapy are typical treatment tools, along with palliative therapy to help control or reduce symptoms. There are also drugs currently under study in the areas of both targeted therapy and immunotherapy.

It's good to know that gallbladder cancer is rare -- and that it takes far fewer lives than breast cancer and other diseases -- but for the unfortunate ones who are diagnosed with this life-threatening illness, the lack of information and resources is a truly an unfortunate side effect.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.